Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Brief Summary: Evaluate efficacy and safety of 16 weeks of titrated dose treatment with BAY85-3934 versus epoetin alfa/beta as measured by hemoglobin (Hb) levels. Fixed starting doses of 25, 50,75 and 150 mg of BAY85-3934 titrated at the scheduled dose control visits. Titration will be based on the subject's Hb response and tolerability of the prior dose. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg/day


Options:
A: Arm Label: FG-4592; Type: EXPERIMENTAL; Interventions: Drug: FG-4592 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FG-4592; Assigned to Arm(s): FG-4592 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: GSK1278863 4 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 6 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 8 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 10 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 12 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: rhEPO | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): GSK1278863 10 mg, GSK1278863 12 mg, GSK1278863 4 mg, GSK1278863 6 mg, GSK1278863 8 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: rhEPO; Assigned to Arm(s): Control
C: Arm Label: Molidustat (BAY 85-3934)(25mg); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY 85-3934) | Arm Label: Molidustat (BAY 85-3934)(50mg); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY 85-3934) | Arm Label: Molidustat (BAY 85-3934) (75mg); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY 85-3934) | Arm Label: Molidustat (BAY 85-3934) (150mg); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY 85-3934) | Arm Label: Epoetin alfa/beta; Type: ACTIVE_COMPARATOR; Interventions: Biological: Epoetin alfa/beta | Intervention Type: DRUG; Name: Molidustat (BAY 85-3934); Assigned to Arm(s): Molidustat (BAY 85-3934) (150mg), Molidustat (BAY 85-3934) (75mg), Molidustat (BAY 85-3934)(25mg), Molidustat (BAY 85-3934)(50mg) | Intervention Type: BIOLOGICAL; Name: Epoetin alfa/beta; Assigned to Arm(s): Epoetin alfa/beta
D: Arm Label: Roxadustat 0.7 mg/kg BIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 0.7 mg/kg TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 1.0 mg/kg BIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 1.0 mg/kg TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 1.5 mg/kg BIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 1.5 mg/kg TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 2.0 mg/kg BIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 2.0 mg/kg TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat 0.7 mg/kg BIW, Roxadustat 0.7 mg/kg TIW, Roxadustat 1.0 mg/kg BIW, Roxadustat 1.0 mg/kg TIW, Roxadustat 1.5 mg/kg BIW, Roxadustat 1.5 mg/kg TIW, Roxadustat 2.0 mg/kg BIW, Roxadustat 2.0 mg/kg TIW | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C